2022
Artax Biopharma Expands Company’s Scientific Advisory Board
16/11/2022Company Welcomes James G. Krueger, M.D., Ph.D., and Ajay Nirula, M.D., Ph.D., Both Experts in T-Cell-Mediated Diseases. Cambridge, MA, November 15,... Read More
AURA announces the design of a global phase 3 trial of Bel-Sar
11/11/2022Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap... Read More
Strategic alliance between Minoryx and Neuraxpharm
10/11/2022Minoryx and Neuraxpharm announce a strategic alliance to provide a new therapy for rare CNS disease patients in Europe The companies... Read More
Aleta Biotherapeutics Receives Innovation Passport Designation for Biologic CAR T-Cell Therapy Engager ALETA-001
08/11/2022Aleta Biotherapeutics Receives Innovation Passport Designation for Biologic CAR T-Cell Therapy Engager ALETA-001. Designation Intends to Accelerate Regulatory Review Process and... Read More
Cleon Capital and Columbus Venture Partners announce the divestment of Spanish biotech company Algenex
10/10/2022Cleon Capital and Columbus Venture Partners announce the divestment of Spanish biotech company Algenex. Insud's acquisition of the company highlights the... Read More
Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer
04/10/2022Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with... Read More
Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer
29/09/2022Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder... Read More
Minoryx submits a marketing authorisation application for its drug leriglitazone for the treatment of X-ALD.
15/09/2022X-linked adrenoleukodystrophy (X-ALD) is a rare, neurodegenerative disease for which there is no treatment. Mataró, Barcelona, Spain, September 14, 2022 –... Read More
Columbus VP leads the new investment round of Integra Therapeutics with €1.5M
30/03/2022The biotechnology firm completes the seed round funding with a total of €6 million led last December by AdBio Partners, Invivo... Read More